Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 947-964
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 199
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 3, pp. 436-448
Open Access | Times Cited: 14
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink
Cornelius James Fernandez, Mohammed Alkhalifah, Hafsa Afsar, et al.
Pathogens (2024) Vol. 13, Iss. 1, pp. 68-68
Open Access | Times Cited: 11
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Maria Eva Argenziano, Mi Na Kim, Michele Montori, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 922-940
Closed Access | Times Cited: 8
Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes
Maurice Stephan Michel, Michelle Doll, Nastasia Albert, et al.
United European Gastroenterology Journal (2024) Vol. 12, Iss. 1, pp. 11-21
Open Access | Times Cited: 6
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials
Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 836-848
Open Access | Times Cited: 6
Body Composition in Chronic Liver Disease
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 964-964
Open Access | Times Cited: 5
Metabolic reprogramming in hepatocellular carcinoma: a bibliometric and visualized study from 2011 to 2023
Xia Li, Liping Zhou, Xinyi Xu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Remnant cholesterol, a potential risk factor of metabolic dysfunction-associated fatty liver disease
Xuanyu Hao, Dongyang Li, Xingyong Huang, et al.
Nutrition & Metabolism (2025) Vol. 22, Iss. 1
Open Access
Fibroblast growth factor receptor signaling in metabolic dysfunction-associated fatty liver disease: Pathogenesis and therapeutic targets
Yi Chu, Yang Su, Xiaodong Chen
Pharmacology & Therapeutics (2025), pp. 108844-108844
Closed Access
Association of serum iron status with MASLD and liver fibrosis
Wenying Guo, Ting Weng, Yufei Song
PLoS ONE (2025) Vol. 20, Iss. 4, pp. e0319057-e0319057
Open Access
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Ilaria Milani, Marianna Chinucci, Frida Leonetti, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 855-855
Open Access
Association between allopurinol and hepatocellular carcinoma: analysis of genetic risk and patient survival
Yufu Li, Huiwei Wang, Haichuan Peng, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Nuclear magnetic resonance-based lipid metabolite profiles for differentiation of patients with liver cirrhosis with and without hepatocellular carcinoma
L Nardone, Marianna Alunni‐Fabbroni, Regina Schinner, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 4
Open Access
Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Nahúm Méndez‐Sánchez, Willem Pieter Brouwer, Frank Lammert, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 884-896
Open Access | Times Cited: 3
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 4, pp. 705-708
Open Access | Times Cited: 2
MASLD: an emerging factor in the pathophysiology and clinical management of ICC
Zong‐Long Li, Jia-Lu Chen, Yue Tang, et al.
Hepatoma Research (2024)
Open Access | Times Cited: 2
Chronic stress alters hepatic metabolism and thermodynamic respiratory efficiency affecting epigenetics in C57BL/6 mice
Aleksandra Nikolic, Pia Fahlbusch, Nele-Kathrien Riffelmann, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109276-109276
Open Access | Times Cited: 1
Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study
Lin Tuo, Liting Yan, Yi Liu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 1
Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma
Min Yao, Rong-Fei Fang, Qun Xie, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 6, pp. 2350-2361
Open Access | Times Cited: 1
Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation
Lingling Wang, Yuming Lu, Yihan Wang, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 47, pp. 5055-5069
Closed Access | Times Cited: 1
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink
Cornelius James Fernandez, Mohammed Alkhalifah, Hafsa Afzar, et al.
(2023)
Open Access | Times Cited: 2
A Case of Secondary Growth Hormone Deficiency that Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy
Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, et al.
Internal Medicine (2024)
Open Access
The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men
Dong‐Hua Bin, Fang Liu, Ke‐Ping Peng, et al.
Nutrition and Diabetes (2024) Vol. 14, Iss. 1
Open Access
Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Centura R. Anbarasu, Sophia Williams‐Perez, E. Ramsay Camp, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2773-2773
Open Access
Page 1 - Next Page

Scroll to top